Share

July 23, 2013; 81 (4) Article

Inverse occurrence of cancer and Alzheimer disease

A population-based incidence study

Massimo Musicco, Fulvio Adorni, Simona Di Santo, Federica Prinelli, Carla Pettenati, Carlo Caltagirone, Katie Palmer, Antonio Russo
First published July 10, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31829c5ec1
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
670

Share

Article Information

vol. 81 no. 4 322-328
DOI: 
https://doi.org/10.1212/WNL.0b013e31829c5ec1
PubMed: 
23843468
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 29, 2013
  • Accepted in final form March 27, 2013
  • First Published July 10, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Massimo Musicco, MD,
    2. Fulvio Adorni, PhD,
    3. Simona Di Santo, MSc,
    4. Federica Prinelli, MSc,
    5. Carla Pettenati, MD,
    6. Carlo Caltagirone, MD,
    7. Katie Palmer, PhD and
    8. Antonio Russo, MD
  1. Massimo Musicco, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) In the last 3 years I received an unconditioned research grant from Abbott Italy for a multi center research on RSV infections in children. 2) In the last two years I received an unconditioned research grant from Novartis for a multi center research on Goal Attainment Scale in patients with Alzheimer's disease. These grants were ruled by specific contracts with my Institution (National Research Council of Italy)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Fulvio Adorni, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Simona Di Santo, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. “The Journal of Alzheimer's Disease”, associate editor, 2013. (no compensation) “Yonsei Medical Journal”, referee, 2013. (no compensation)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Federica Prinelli, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Carla Pettenati, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. honoraria from Lundbeck for teaching course

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Carlo Caltagirone, MD,
    7. Scientific Advisory Boards:

    1. From Lilly, as a member of the Scientific Advisory Board in 2011-2012, from Novartis, as a member of the Scientific Advisory Board, in 2011-2012.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Italian Ministry of Health RF97, year 2011-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Katie Palmer, PhD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Antonio Russo, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Lombardy Regional Authority, Cancer Registry, Principal Investigator, 2011, 2012 (2) Lombardy Regional Authority, Oncologic Indicators, Principal Investigator, 2011, 2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Research Council of Italy (M.M., F.A., F.P.), Institute of Biomedical Technologies, Segrate (Milan); Foundation IRCCS “Santa Lucia” (M.M., S.D., C.C., K.P.), Rome; Alzheimer Departmental Unit (C.P.), AO of Garbagnate (Milan); University “Tor Vergata” (C.C.), Rome; and Epidemiology Unit (A.R.), Local Health Authority of Milano 1, Milan, Italy.
  1. Correspondence to Dr. Musicco: massimo.musicco{at}itb.cnr.it
View Full Text

Article usage

Article usage: July 2013 to December 2022

AbstractFullPdfSource
Jul 2013686736233Highwire
Aug 201324042244Highwire
Sep 201310761218Highwire
Oct 201311341931Highwire
Nov 201310421519Highwire
Dec 2013801511Highwire
Jan 201478859Highwire
Feb 201491159Highwire
Mar 2014688910Highwire
Apr 201449945Highwire
May 201460547Highwire
Jun 201437315Highwire
Jul 201428166Highwire
Aug 201464422Highwire
Sep 201484513Highwire
Oct 201445745Highwire
Nov 201472247Highwire
Dec 201455503Highwire
Jan 201514249Highwire
Feb 20159633Highwire
Mar 201515788Highwire
Apr 201510967Highwire
May 201512735Highwire
Jun 201513714Highwire
Jul 201516142Highwire
Aug 201517633Highwire
Sep 201516541Highwire
Oct 201513886Highwire
Nov 201510255Highwire
Dec 201513033Highwire
Jan 201611545Highwire
Feb 20166320Highwire
Mar 20166654Highwire
Apr 20166201Highwire
May 20167966Highwire
Jun 20169975Highwire
Jul 20167612Highwire
Aug 20168774Highwire
Sep 20169824Highwire
Oct 201612822Highwire
Nov 201615121Highwire
Dec 201610333Highwire
Jan 201720264Highwire
Feb 201717833Highwire
Mar 201710841Highwire
Apr 201718000Highwire
May 201711901Highwire
Jun 20176911Highwire
Jul 20174240Highwire
Aug 20175721Highwire
Sep 20179511Highwire
Oct 20178911Highwire
Nov 201711812Highwire
Dec 20175743Highwire
Jan 20187123Highwire
Feb 20185921Highwire
Mar 20186352Highwire
Apr 20187350Highwire
May 20189831Highwire
Jun 20189100Highwire
Jul 20188210Highwire
Aug 201819211Highwire
Sep 20185012Highwire
Oct 20186553Highwire
Nov 201812614Highwire
Dec 20186901Highwire
Jan 20195602Highwire
Feb 20197700Highwire
Mar 20197021Highwire
Apr 20196632Highwire
May 20195621Highwire
Jun 20193732Highwire
Jul 20194792Highwire
Aug 20196000Highwire
Sep 20194355Highwire
Oct 20195223Highwire
Nov 20199423Highwire
Dec 20197001Highwire
Jan 202010335Highwire
Feb 20207410Highwire
Mar 20207182Highwire
Apr 20205713Highwire
May 20207413Highwire
Jun 20208033Highwire
Jul 20206701Highwire
Aug 20209710Highwire
Sep 20205878Highwire
Oct 202011312Highwire
Nov 20209231Highwire
Dec 20206713Highwire
Jan 20218611Highwire
Feb 20218712Highwire
Mar 20219343Highwire
Apr 202111723Highwire
May 202114814Highwire
Jun 20217213Highwire
Jul 20217600Highwire
Aug 20215023Highwire
Sep 20215621Highwire
Oct 20215833Highwire
Nov 20219512Highwire
Dec 202110911Highwire
Jan 20228274Highwire
Feb 20228545Highwire
Mar 20229333Highwire
Apr 20227633Highwire
May 20227611Highwire
Jun 20225632Highwire
Jul 202210034Highwire
Aug 202212631Highwire
Sep 20229745Highwire
Oct 20228033Highwire
Nov 20226620Highwire
Dec 2022106114Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me